Director, Patient Experience and Access Marketing

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Learn more about us at www.madrigalpharma.com